Immunome/$IMNM
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Immunome
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Ticker
$IMNM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
131
ISIN
US45257U1088
Website
Immunome Metrics
BasicAdvanced
$794M
-
-$3.13
2.01
-
Price and volume
Market cap
$794M
Beta
2.01
52-week high
$16.81
52-week low
$5.15
Average daily volume
966K
Financial strength
Current ratio
10.492
Quick ratio
10.304
Long term debt to equity
1.553
Total debt to equity
1.553
Management effectiveness
Return on assets (TTM)
-33.54%
Return on equity (TTM)
-69.21%
Valuation
Price to revenue (TTM)
54.702
Price to book
2.58
Price to tangible book (TTM)
2.58
Price to free cash flow (TTM)
-3.345
Growth
Revenue change (TTM)
-13.76%
Earnings per share change (TTM)
-60.00%
3-year earnings per share growth (CAGR)
4.67%
What the Analysts think about Immunome
Analyst ratings (Buy, Hold, Sell) for Immunome stock.
Immunome Financial Performance
Revenues and expenses
Immunome Earnings Performance
Company profitability
Immunome News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunome stock?
Immunome (IMNM) has a market cap of $794M as of June 06, 2025.
What is the P/E ratio for Immunome stock?
The price to earnings (P/E) ratio for Immunome (IMNM) stock is 0 as of June 06, 2025.
Does Immunome stock pay dividends?
No, Immunome (IMNM) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Immunome dividend payment date?
Immunome (IMNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunome?
Immunome (IMNM) has a beta rating of 2.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.